Incidence of hand-foot syndrome with protein kinase inhibitors in advanced hepatocellular carcinoma patients who received atezolizumab-bevacizumab combination.

Fiche publication

Date publication

août 2024

Journal

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Perrier M, Zuccaro E, Carlier C, Brugel M, Slimano F, Bouché O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39090999

Résumé

Treatment of advanced HepatoCellular Carcinoma (HCC) is based on first-line (L1) combination of atezolizumab and high-dose (HD) bevacizumab while second-line (L2) refers one antiangiogenic protein kinase inhibitors (aaPKI). This prolonged antiangiogenic pressure let us to observe an increasing occurrence of Hand-Foot Syndromes (HFS) in patients receiving aaPKI after HD bevacizumab combination. This study reports observations and discussions about the evidence and hypothesis that could be made.